Antibacterial activity of Veraflox (pradofloxacin) oral suspension in vitro and application for the treatment of infections in parrots
Keywords:
parrots, infections, Veraflox, pradofloxacin, enrofloxacin, antibacterial activityAbstract
Microbiological studies on materials from 217 parrots with various infections have been performed that showed a significant prevalence of the staphylococcal diseases (39.7% of isolates) in
these birds, followed by streptococcal ones (33.7%). The isolated Gram-negative bacteria (17.4%)
and fungi (9.2%) were less. The role of S. aureus as an infectious agent in the parrots was leading,
and from Gram-negative species – of Klebsiella spp. (in 8.7% of the patients studied), E. coli and
Moraxella catarrhalis.
The major part (95.4%) of the isolated 197 bacterial strains of 217 parrots showed sensitivity in
vitro to Veraflox (a suspension for oral administration containing pradofloxacin), determined by
the classical disk agar-gel diffusion method. Resistance was only detected in single staphylococcal and enterococcal strains. All patients treated with it after a positive result of the antibiogram
were permanently cured (94.7%), with the exception of 10 birds (5.3%) that came for examination
and treatment in very serious condition. Veraflox oral suspension has been found to be an excellent mean for treating various parrot infections. The dose (15 mg/kg bw) and the frequency of oral
administration (24 h) at which an antimicrobial effect occurs without any adverse side effects for
the patient have been successfully determined. This is the first report for use of Veraflox in our
country and in the world for the treatment of parrots with various infections.
Determination of the minimum inhibitory concentrations (MIC) was also performed to accurately assess the antibacterial effect of Veraflox against S. aureus and E. coli. The bacterial strains
tested showed high sensitivity to pradofloxacin as well as to the control quinolone enrofloxacin,
although the inhibitory effect of enrofloxacin was higher. The susceptibility of tested strains of S.
aureus to pradofloxacin was lower than that of E. coli strains. The mean MIC50 values of this quinolone for the Gram-positive bacteria S. aureus (0.25 ± 0.12 μg/ml) were higher than those for the
Gram-negative E. coli (0.18 ± 0.06 μg/ml), with significant differences (P < 0.05). The results obtained when determining sensitivity to enrofloxacin were opposite. The development of the tested
strains of S. aureus was suppressed by significantly lower concentrations of this quinolone than
those for E. coli. The reported mean MIC50 values for S. aureus were 0.018 ± 0.008 μg/ml, while
those for E. coli – 0.044 ± 0.015 μg/ml.
References
Bauer, A. W., Kirby, W. M., Cherris, J. C., & Truck, M. (1966). Antibiotic susceptibility testing by a standardized single disk method. The American. Journal. of Clinical Pathology, 45 (4), 493-496.
Ericsson, H. M., & Sherris, J. C. (1971). Antibiotic sensitivity testing. Report of an international collaborative study. Acta pathologica et microbiologica scandinavica, (Suppl. 217), 3-86.
Govendir, M., Norris, J. M., Hansen, T., Wigney, D. I., Muscatello, G., Trott, D. J., & Malik, R. (2011). Susceptibility of rapidly growing mycobacteria and Nocardia isolates from cats and dogs to pradofloxacin. Veterinary microbiology, 153(3-4), 240-245.
Holt, J. G., Krieg, N. R., Sneart, P. H. A., Staley, J. T., & Williams, S. T. (1994). Bergey’s manual of determinative bacteriology. Ninth edition, Baltimore, Williams & Wilkins.
Hooper, D. C. (2000). Mechanisms of action and resistance of older and newer fluoroquinolones. Clinical Infectious Diseases, 31(Supplement_2), S24-S28. 13
Kizerwetter-Świda, M., Chrobak-Chmiel, D., Rzewuska, M., & Binek, M. (2016). Resistance of canine methicillin-resistant Staphylococcus pseudintermedius strains to pradofloxacin. Journal of Veterinary Diagnostic Investigation, 28, (5), 514-518. DOI: 10.1177/1040638716660131 jvdi.sagepub.com.
Lees, P. (2013). Pharmacokinetics, pharmacodynamics and therapeutics of pradofloxacin in the dog and cat. Journal of veterinary pharmacology and therapeutics, 36(3), 209-221. DOI: 10.1111/jvp.12036.
Murray, P. R., Baron, E. J., Jorgensen, J. H., Pfaller, M. A., & Yolken, R. H. (2003). Mannual of Clinical Microbiology. 8th Edition, Vol. 2, ASM Press, Washington, D. C., 1726-1760.
Pallo-Zimmerman, L. M., Byron, J. K., & Graves, T. K. (2010). Fluoroquinolones: then and now. Compend Contin Educ Vet, 32(7), E1-9.
Papich, M. G. (2016). Pradofloxacin. In: Saunders Handbook of Veterinary Drugs. (Fourth Edition), Small and Large Animal, 660-662.
Popova, T. P., & Todorov, T. A. (2008). In vitro antimicrobial activity of enrofloxacin against clinical isolates from dogs and cats in Bulgaria. Folia Veterinaria, 52(3-4), 124-128. ISSN 0015-5748.
Scheer, M. (1987). Studies on the antibacterial activity of Baytril. Veterinary Medical Review, 2, 90-99.
Schink, A. K., Kadlec, K., Hauschild, T., Michael, G. B., Dörner, J. C., Ludwig, C., Werckenthin, C., Hehnen, H. R., Stephan, B., & Schwarz, S. (2013). Susceptibility of canine and feline bacterial pathogens to pradofloxacin and comparison with other fluoroquinolones approved for companion animals. Veterinary microbiology,22, 162(1), 119-126. DOI: 10.1016/j.vetmic.2012.08.001.
Silley, P., Stephan, B., Greife, H. A., & Pridmore, A. (2007). Comparative activity of pradofloxacin against anaerobic bacteria isolated from dogs and cats. Journal of antimicrobial chemotherapy, 60(5), 999-1003. https://doi.org/10.1093/jac/dkm346.
Silley, P., Stephan, B., Greife, H. A., & Pridmore, A. (2012). Bactericidal properties of pradofloxacin against veterinary pathogens. Veterinary microbiology, 157(1-2), 106-111.
Stephan, B., Greife, H. A., Pridmore, A., & Silley, P. (2008). Activity of pradofloxacin against porphyromonas and prevotella spp. implicated in periodontal disease in dogs: susceptibility test data from a European multicenter study. Antimicrobial agents and chemotherapy, 52(6), 2149-2155.
National Committee for Clinical Laboratory Standards: Performance Standards for Antimicrobial Disk Susceptibility Tests. 6-th ed. Approved Standard. NCCLS Document M2 – A6, 17, 1, 1997.
National Committee for Clinical Laboratory Standards: Performance Standards for Antimicrobial Susceptibility Testing: Ninths Informational Supplement. NCCLS Document M100 – S9, Vol. 18, No 1, 1999.
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2024 Bulgarian Journal of Animal Husbandry
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
